Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?lookfor=%2522WHO+International+Clinical+Trials+Registry+Platform%2522&type=JournalTitle&sort=year
/vufind/Search/Results?lookfor=%2522WHO+International+Clinical+Trials+Registry+Platform%2522&type=JournalTitle&sort=year
Search /vufind/Search2/Results?lookfor=%2522WHO+International+Clinical+Trials+Registry+Platform%2522&type=JournalTitle&sort=year
PubPharm (44.224)
1
A study of enfortumab vedotin in patients with locally advanced or metastatic urothelial bladder cancer : A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy.
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
2
A study of enfortumab vedotin in patients with locally advanced or metastatic urothelial bladder cancer : A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy.
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
3
Phase I trial, HMR code: 22-016 : Phase I trial, HMR code: 22-016 [The full scientific title will be published within 30 months after the end of the trial]
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
4
Phase I trial HMR code: 22-014 : Phase I trial HMR code: 22-014 [The full scientific title will be published within 30 months after the end of the trial]
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
5
Phase I trial, HMR code: 22-016 : Phase I trial, HMR code: 22-016 [The full scientific title will be published within 30 months after the end of the trial]
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
6
Phase I trial HMR code: 22-014 : Phase I trial HMR code: 22-014 [The full scientific title will be published within 30 months after the end of the trial]
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
7
A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD˗9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure : A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD˗9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
8
A PHASE 2/2B, RANDOMIZED TRIAL TO EVALUATE THE SAFETY, IMMUNOGENICITY AND EFFICACY OF A ZIKA VIRUS DNA VACCINE IN HEALTHY ADULTS AND ADOLESCENTS : A PHASE 2/2B, RANDOMIZED TRIAL TO EVALUATE THE SAFETY, IMMUNOGENICITY AND EFFICACY OF A ZIKA VIRUS DNA VACCINE IN HEALTHY ADULTS AND ADOLESCENTS
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
9
An Open-Label, Randomized, Phase 3 Study of Inotuzumab Ozogamicin (CMC-544) Administered in Combination With Rituximab Compared to a Defined Investigator’s Choice Therapy in Subjects With Relapsed or Refractory, CD22- Positive, Follicular B-Cell Non Hodgkin’s Lymphoma : An Open-Label, Randomized, Phase 3 Study of Inotuzumab Ozogamicin (CMC-544) Administered in Combination With Rituximab Compared to a Defined Investigator’s Choice Therapy in Subjects With Relapsed or Refractory, CD22- Positive, Follicular B-Cell Non Hodgkin’s Lymphoma
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
10
A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD˗9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure : A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD˗9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
1
2
3
4
5
6
7
8
9
10
11
Nächster »
[4423]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Medienart
44.224
Aufsätze
44.224
E-Artikel
44.224
E-Ressourcen
Zeitschriftentitel
44.224
WHO International Clinical Trials Registry Plat...
Thema
44.146
610
41.900
Study Type: Interventional
31.068
Recruitment Status: Completed
6.528
Recruitment Status: Not yet recruiting
5.100
Recruitment Status: Recruiting
4.670
Phase: Phase 2/Phase 3
1.672
Phase: Phase 3
1.654
Study Type: Observational
1.068
Phase: Phase 2
968
Recruitment Status: Authorised-recruitment may ...
470
Phase: Phase 1/Phase 2
382
Phase: Phase 1
352
Phase: Phase 4
334
Phase: Retrospective study
260
Phase: Phase 0
252
Phase: New Treatment Measure Clinical Study
230
Phase: Other
212
Study Type: Diagnostic test
158
Recruitment Status: Other
102
Study Type: Relative factors research
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
8.368
2020-
35.856
2010-2019
Erscheinungsjahr(e)
Von:
Bis:
Sprache
43.826
Englisch
330
Unbestimmt
22
Spanisch
12
Französisch
12
Deutsch
8
Dänisch
4
Niederländisch
2
Finnisch
2
Isländisch
2
Latein
2
Schwedisch
2
Türkisch
Alle anzeigen ...
weniger ...
Haven't found what you're looking for?
Wird geladen...